Mymetics Corp (MYMX)

[Work Harder]

Feb 21, 2013 Preclinical studies in non-human primates already generated extremely promising data demonstrating 100% protection against multiple intra-vaginal challenges with a live virus."

Providing Mymetics obtains additional sources of financing for this project, the company plans to test its prophylactic HIV-1 vaccine candidate in a combined Phase I and II trial to investigate an additional HIV-1 antigen and a further optimized vaccine formulation.

https://finance.yahoo.com/news/data-published-plos-one-show-073000012.html?fr=sycsrp_catchall

Pending this data, a combined Phase I/II on women and men might start by 2022.

https://www.otcmarkets.com/filing/html?id=14842380&guid=wYWwk621Ej5cdth

Pending this data, a combined Phase I/II on women and men might start by 2021

https://www.otcmarkets.com/filing/html?id=14041707&guid=wYWwk621Ej5cdth

We are eagerly awaiting the results of our NIH-funded project

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167129437

They are clearly working on Hiv

& Intl says bye

LOL